As a composite indicator based on fibrinogen and albumin, FAR has been reported to be a potential predictor of adverse outcomes in various malignancies, such as esophageal squamous cell carcinoma (30), hepatocellular carcinoma (31), and NSCLC (28). Here, ALB is linked to non-small cell lung carcinoma.